<?xml version='1.0' encoding='utf-8'?>
<document id="26202880"><sentence text="Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography." /><sentence text="The adenosine triphosphate-binding cassette transporter P-glycoprotein (ABCB1/Abcb1a) restricts at the blood-brain barrier (BBB) brain distribution of many drugs"><entity charOffset="4-26" id="DDI-PubMed.26202880.s2.e0" text="adenosine triphosphate" /></sentence><sentence text=" ABCB1 may be involved in drug-drug interactions (DDIs) at the BBB, which may lead to changes in brain distribution and central nervous system side effects of drugs" /><sentence text=" Positron emission tomography (PET) with the ABCB1 substrates (R)-[(11)C]verapamil and [(11)C]-N-desmethyl-loperamide and the ABCB1 inhibitor tariquidar has allowed direct comparison of ABCB1-mediated DDIs at the rodent and human BBB"><entity charOffset="62-82" id="DDI-PubMed.26202880.s4.e0" text="(R)-[(11)C]verapamil" /><entity charOffset="87-117" id="DDI-PubMed.26202880.s4.e1" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s4.e0" e2="DDI-PubMed.26202880.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s4.e0" e2="DDI-PubMed.26202880.s4.e1" /></sentence><sentence text=" In this work we evaluated different factors which could influence the magnitude of the interaction between tariquidar and (R)-[(11)C]verapamil or [(11)C]-N-desmethyl-loperamide at the BBB and thereby contribute to previously observed species differences between rodents and humans"><entity charOffset="123-143" id="DDI-PubMed.26202880.s5.e0" text="(R)-[(11)C]verapamil" /><entity charOffset="147-177" id="DDI-PubMed.26202880.s5.e1" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s5.e0" e2="DDI-PubMed.26202880.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s5.e0" e2="DDI-PubMed.26202880.s5.e1" /></sentence><sentence text=" We performed in vitro transport experiments with [(3)H]verapamil and [(3)H]-N-desmethyl-loperamide in ABCB1 and Abcb1a overexpressing cell lines"><entity charOffset="50-65" id="DDI-PubMed.26202880.s6.e0" text="[(3)H]verapamil" /><entity charOffset="70-99" id="DDI-PubMed.26202880.s6.e1" text="[(3)H]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s6.e0" e2="DDI-PubMed.26202880.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s6.e0" e2="DDI-PubMed.26202880.s6.e1" /></sentence><sentence text=" Moreover we conducted in vivo PET experiments and biodistribution studies with (R)-[(11)C]verapamil and [(11)C]-N-desmethyl-loperamide in wild-type mice without and with tariquidar pretreatment and in homozygous Abcb1a/1b((-/-)) and heterozygous Abcb1a/1b((+/-)) mice"><entity charOffset="80-100" id="DDI-PubMed.26202880.s7.e0" text="(R)-[(11)C]verapamil" /><entity charOffset="105-135" id="DDI-PubMed.26202880.s7.e1" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s7.e0" e2="DDI-PubMed.26202880.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s7.e0" e2="DDI-PubMed.26202880.s7.e1" /></sentence><sentence text=" We found no differences for in vitro transport of [(3)H]verapamil and [(3)H]-N-desmethyl-loperamide by ABCB1 and Abcb1a and its inhibition by tariquidar"><entity charOffset="51-66" id="DDI-PubMed.26202880.s8.e0" text="[(3)H]verapamil" /><entity charOffset="71-100" id="DDI-PubMed.26202880.s8.e1" text="[(3)H]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s8.e0" e2="DDI-PubMed.26202880.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s8.e0" e2="DDI-PubMed.26202880.s8.e1" /></sentence><sentence text=" [(3)H]-N-Desmethyl-loperamide was transported with a 5 to 9 times higher transport ratio than [(3)H]verapamil in ABCB1- and Abcb1a-transfected cells"><entity charOffset="1-30" id="DDI-PubMed.26202880.s9.e0" text="[(3)H]-N-Desmethyl-loperamide" /><entity charOffset="95-110" id="DDI-PubMed.26202880.s9.e1" text="[(3)H]verapamil" /><pair ddi="false" e1="DDI-PubMed.26202880.s9.e0" e2="DDI-PubMed.26202880.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s9.e0" e2="DDI-PubMed.26202880.s9.e1" /></sentence><sentence text=" In vivo, brain radioactivity concentrations were lower for [(11)C]-N-desmethyl-loperamide than for (R)-[(11)C]verapamil"><entity charOffset="60-90" id="DDI-PubMed.26202880.s10.e0" text="[(11)C]-N-desmethyl-loperamide" /><entity charOffset="100-120" id="DDI-PubMed.26202880.s10.e1" text="(R)-[(11)C]verapamil" /><pair ddi="false" e1="DDI-PubMed.26202880.s10.e0" e2="DDI-PubMed.26202880.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s10.e0" e2="DDI-PubMed.26202880.s10.e1" /></sentence><sentence text=" Both radiotracers showed tariquidar dose dependent increases in brain distribution with tariquidar half-maximum inhibitory concentrations (IC50) of 1052 nM (95% confidence interval CI: 930-1189) for (R)-[(11)C]verapamil and 1329 nM (95% CI: 980-1801) for [(11)C]-N-desmethyl-loperamide"><entity charOffset="200-220" id="DDI-PubMed.26202880.s11.e0" text="(R)-[(11)C]verapamil" /><entity charOffset="238-240" id="DDI-PubMed.26202880.s11.e1" text="CI" /><entity charOffset="256-286" id="DDI-PubMed.26202880.s11.e2" text="[(11)C]-N-desmethyl-loperamide" /><entity charOffset="182-211" id="DDI-PubMed.26202880.s11.e3" text="CI" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e3" e2="DDI-PubMed.26202880.s11.e3" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e3" e2="DDI-PubMed.26202880.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e3" e2="DDI-PubMed.26202880.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e3" e2="DDI-PubMed.26202880.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e0" e2="DDI-PubMed.26202880.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e0" e2="DDI-PubMed.26202880.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e0" e2="DDI-PubMed.26202880.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e1" e2="DDI-PubMed.26202880.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s11.e1" e2="DDI-PubMed.26202880.s11.e2" /></sentence><sentence text=" In homozygous Abcb1a/1b((-/-)) mice brain radioactivity distribution was increased by 3" /><sentence text="9- and 2" /><sentence text="8-fold and in heterozygous Abcb1a/1b((+/-)) mice by 1" /><sentence text="5- and 1" /><sentence text="1-fold, for (R)-[(11)C]verapamil and [(11)C]-N-desmethyl-loperamide, respectively, as compared with wild-type mice"><entity charOffset="0-6" id="DDI-PubMed.26202880.s16.e0" text="1-fold" /><entity charOffset="12-32" id="DDI-PubMed.26202880.s16.e1" text="(R)-[(11)C]verapamil" /><entity charOffset="37-67" id="DDI-PubMed.26202880.s16.e2" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s16.e0" e2="DDI-PubMed.26202880.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s16.e0" e2="DDI-PubMed.26202880.s16.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s16.e0" e2="DDI-PubMed.26202880.s16.e2" /><pair ddi="false" e1="DDI-PubMed.26202880.s16.e1" e2="DDI-PubMed.26202880.s16.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s16.e1" e2="DDI-PubMed.26202880.s16.e2" /></sentence><sentence text=" For both radiotracers radiolabeled metabolites were detected in plasma and brain" /><sentence text=" When brain and plasma radioactivity concentrations were corrected for radiolabeled metabolites, brain distribution of (R)-[(11)C]verapamil and [(11)C]-N-desmethyl-loperamide was increased in tariquidar (15 mg/kg) treated animals by 14"><entity charOffset="119-139" id="DDI-PubMed.26202880.s18.e0" text="(R)-[(11)C]verapamil" /><entity charOffset="144-174" id="DDI-PubMed.26202880.s18.e1" text="[(11)C]-N-desmethyl-loperamide" /><pair ddi="false" e1="DDI-PubMed.26202880.s18.e0" e2="DDI-PubMed.26202880.s18.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s18.e0" e2="DDI-PubMed.26202880.s18.e1" /></sentence><sentence text="1- and 18" /><sentence text="3-fold, respectively, as compared with vehicle group" /><sentence text=" Isoflurane anesthesia altered [(11)C]-N-desmethyl-loperamide but not (R)-[(11)C]verapamil metabolism, and this had a direct effect on the magnitude of the increase in brain distribution following ABCB1 inhibition"><entity charOffset="1-11" id="DDI-PubMed.26202880.s21.e0" text="Isoflurane" /><entity charOffset="31-61" id="DDI-PubMed.26202880.s21.e1" text="[(11)C]-N-desmethyl-loperamide" /><entity charOffset="70-90" id="DDI-PubMed.26202880.s21.e2" text="(R)-[(11)C]verapamil" /><pair ddi="false" e1="DDI-PubMed.26202880.s21.e0" e2="DDI-PubMed.26202880.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s21.e0" e2="DDI-PubMed.26202880.s21.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s21.e0" e2="DDI-PubMed.26202880.s21.e2" /><pair ddi="false" e1="DDI-PubMed.26202880.s21.e1" e2="DDI-PubMed.26202880.s21.e1" /><pair ddi="false" e1="DDI-PubMed.26202880.s21.e1" e2="DDI-PubMed.26202880.s21.e2" /></sentence><sentence text=" Our data furthermore suggest that in the absence of ABCB1 function brain distribution of [(11)C]-N-desmethyl-loperamide but not (R)-[(11)C]verapamil may depend on cerebral blood flow"><entity charOffset="90-120" id="DDI-PubMed.26202880.s22.e0" text="[(11)C]-N-desmethyl-loperamide" /><entity charOffset="129-149" id="DDI-PubMed.26202880.s22.e1" text="(R)-[(11)C]verapamil" /><pair ddi="false" e1="DDI-PubMed.26202880.s22.e0" e2="DDI-PubMed.26202880.s22.e0" /><pair ddi="false" e1="DDI-PubMed.26202880.s22.e0" e2="DDI-PubMed.26202880.s22.e1" /></sentence><sentence text=" In conclusion, we have identified a number of important factors, i" /><sentence text="e" /><sentence text=", substrate affinity to ABCB1, brain uptake of radiolabeled metabolites, anesthesia, and cerebral blood flow, which can directly influence the magnitude of ABCB1-mediated DDIs at the BBB and should therefore be taken into consideration when interpreting PET results" /><sentence text=" " /></document>